FDA Considers Tanezumab Application for Chronic OA Pain

The FDA is considering an application for subcutaneous tanezumab, a monoclonal antibody, as a treatment for moderate to severe osteoarthritis...

Source: The Rheumatologist - April 20, 2020 Category: Rheumatology Authors: Michele B. Kaufman, PharmD, BCGP Tags: Analgesics Drug Updates Chronic pain FDA osteoarthritis (OA) Pain Management tanezumab U.S. Food and Drug Administration (FDA) Source Type: research